2013 BMT Tandem Meetings: Poster Session 2: Transplant Pharmacy

540

Intravenous Busulfan Pharmacokinetics in Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Dosing Weight
Amber M. Bradley, PharmD, Georgia Health Sciences Medical Center; Sarah Evans, PharmD Candidate, University of Georgia College of Pharmacy; David DeRemer, PharmD, BCOP, Georgia Health Sciences Medical Center; Farrukh Tauseef Awan, MD, Georgia Health Sciences University

541

Description of Adverse Drug Events Associated with High-Dose Undiluted Etoposide (VP-16) Among Hematopoietic Stem Cell Transplant Recipients
Catherine Weber, PharmD, BCOP, Cleveland Clinic; Kelley Carlstrom, PharmD, Cleveland Clinic; Matt E. Kalaycio, MD, Cleveland Clinic Foundation

542

Delaying the Start of Triazole Prophylaxis 7 Days After Allogeneic HCT Does Not Affect Outcomes, Including Risk of Invasive Fungal Infection
Kefei Dai, PharmD, Memorial Sloan Kettering Cancer Center; Izaskun Ceberio, MD, Memorial Sloan Kettering Cancer Center; Sean Devlin, PhD, Memorial Sloan-Kettering Cancer Center; Juliet N. Barker, MBBS, (Hons), FRACP, Memorial Sloan-Kettering Cancer Center; Hugo Castro-Malaspina, M.D., Memorial Sloan-Kettering Cancer Center; Jenna Goldberg, MD, Memorial Sloan-Kettering Cancer Center; Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center; Nelly G Adel, PharmD, Memorial Sloan-Kettering Cancer Ctr; Miguel-Angel Perales, MD, Memorial Sloan-Kettering Cancer Center

543

Characterization of Cardiac Arrhythmias Post Allogeneic Transplant
Ashley Elizabeth Glode, PharmD, BCOP, Medical University of South Carolina; Luciano J. Costa, MD, PhD, Medical University of South Carolina

544

Evaluation of Blood Pressure Medication Use Associated with Cyclosporine-Induced Hypertension in the Allogeneic Bone Marrow Transplant Population
Ashley Elizabeth Glode, PharmD, BCOP, Medical University of South Carolina; Kathy Hogan Edwards, PharmD, BCPS, Hollings Cancer Center, Medical University of SC; Daniel Cornett, PharmD, King's Daughters Medical Center; Luciano J. Costa, MD, PhD, Medical University of South Carolina

545

Evaluation of Post-Transplant Iron Chelation Therapy in Allogeneic Hematopoietic Stem Cell Transplant
May Aziz, PharmD, Virginia Commonwealth University Health System; Kelly Gregory, PharmD, BCPS, BCOP, Virginia Commonwealth University Health System; Patricia Corrigan, PharmD, BCOP, Virginia Commonwealth University Health System

546

Linezolid Use Early After Stem Cell Transplant - A Cautionary Tale
Alison Gulbis, PharmD, The University of Texas MD Anderson Cancer Center; Musa Yilmaz, The University of Texas MD Anderson Cancer Center; Dawen Sui, MS, The University of Texas MD Anderson Cancer Center; Roland Bassett Jr., MS, The University of Texas MD Anderson Cancer Center; Zandra Rivera, RN, MS, ANP-BC, The University of Texas MD Anderson Cancer Center; Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center; Marcos de Lima, MD, The University of Texas MD Anderson Cancer Center

547

Association Between Mycophenolic Acid (MPA) Total Serum Trough Levels and Toxicity and Efficacy Outcomes in Cord Blood Transplantation (CBT) Recipients
Stephen Harnicar, PharmD, BCOP, BCPS, Memorial Sloan-Kettering Cancer Center; Doris Ponce, MD, Memorial Sloan-Kettering Cancer Center; David Gregornik, PharmD, Memorial Sloan-Kettering Cancer Center; Katherine Evans, BA, Memorial Sloan-Kettering Cancer Center; Junting Zheng, MS, Memorial Sloan-Kettering Cancer Center; Sean Devlin, PhD, Memorial Sloan-Kettering Cancer Center; Juliet N. Barker, MBBS, (Hons), FRACP, Memorial Sloan-Kettering Cancer Center

548

Incidence of Fluoride Toxicity in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients Taking Voriconazole
Megan Ostrem, Pharm.D., Mayo Clinic; Julianna Merten, PharmD, BCOP, BCPS, Mayo Clinic Rochester; William Hogan, MBBCh, Mayo Clinic; Mark R Litzow, MD, Mayo Clinic; Mrinal Patnaik, MD, Mayo Clinic; Shahrukh Hashmi, MD, MPH, Mayo Clinic; Gabriel Bartoo, PharmD, Mayo Clinic; Robert Wolf, PharmD, Mayo Clinic; Robert Wermers, MD, Mayo Clinic

549

Efficacy of Low-Dose Acyclovir Prophylaxis Against Varicella Zoster Virus in Pediatric Hematopoietic Stem Cell Transplantation Patients
Vinita B Pai, PharmD, MS, Nationwide Children's Hospital; Denitza I Davis, PharmD, Licking Memorial Health Systems; Julie Clayton, RN, Nationwide Children's Hospital; Daniel W Pietryga, MD, Nationwide Children's Hospital

550

Evaluation of Melphalan 1-Day Versus 2-Day Dosing in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Sapna Parmar, PharmD, Moffitt Cancer Center; Ryan Bookout, PharmD, H. Lee Moffitt Cancer Center; Jamie Shapiro, PharmD, H Lee Moffitt Cancer Center; Rebecca Tombleson, PharmD, Moffitt Cancer Center; Janelle Perkins, PharmD, Moffitt Cancer Center; Jongphil Kim, PhD, Moffitt Cancer Center; Melissa Alsina, MD, Moffitt Cancer Center; Taiga Nishihori, MD, H. Lee Moffitt Cancer Center

551

Therapeutic Drug Monitoring (TDM) of Cyclosporine Using the Area Under the Curve in Children Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Roxane Therrien, CHU Ste-Justine; Julien Tourel, CHU Ste-Justine; Lamia Sid-Otmane, CHU Ste-Justine; Michel Duval, CHU Ste-Justine

552

A Prospective, Double-Blinded, Observational Clinical Cohort Study of the Association Between Tacrolimus Exposure and CYP3A4, CYP3A5 Genotypes in Adult Hematopoietic Stem Cell Transplant Recipients
Jigar S Trivedi, MS, PharmD, The Ohio State University Comprehensive Cancer Center; Ming Poi, PharmD, PhD, The Ohio State University Comprehensive Cancer Center; Ali McBride, PharmD, MS, The Ohio State University Comprehensive Cancer Center; Julianna Roddy, PharmD, BCOP, The Ohio State University Comprehensive Cancer Center; Ee Poi, Student Pharmacist, The Ohio State University College of Pharmacy; Jiang Wang, PhD, The Ohio State University Comprehensive Cancer Center; Danxin Wang, PhD, The Ohio State University; Hong Zhu, PhD, The Ohio State University College of Public Health; Elizabeth Marek, Student Pharmacist, The Ohio State University College of Pharmacy; Shamalatha Kolli, Graduate Student, The Ohio State University School of Pharmacy; Wolfgang Sadee, PhD, The Ohio State University; Steven M Devine, MD, The Ohio State University; Niesha Griffith, MS, RPh, FASHP, The Ohio State University Comprehensive Cancer Center; Mitch Phelps, PhD, The Ohio State University, College of Pharmacy

553

Upfront Calcineurin Inhibitor Dose Reduction of 40% in Pediatric Haematopoietic Stem Cell Transplant Does Not Result in Increased Graft Versus Host Disease in Patients Receiving Voriconazole Maintenance Therapy
Felicity A Wright, BPharm MPH, Sydney Children's Hospital; Emma L Davis, BMedSci MPharm, Sydney Children's Hospital; Cecilia Oswald, BSc, Sydney Children's Hospital, Randwick; Tracey O'Brien, FRACP, MBChB, MHL, BSc, Centre for Children's Cancer, Sydney Children's Hospital